Yulei Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Recognitions
Yulei Wang has a total of 721 co-authors. Here are the top co-authors by number of shared publications:
- Amaia Lujambio
Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, USA
15 shared publications - Shannon. J. Turley
Genentech, South San Francisco, CA
14 shared publications - Marina Ruiz de Galarreta
Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, USA
13 shared publications Shan Lu
Department of Translational Medicine, Genentech, Inc., South San Francisco, CA, USA
13 shared publications- Alexander M. Tsankov
Icahn School of Medicine at Mount Sinai
12 shared publications - Alice Oliffson Kamphorst
Marc and Jennifer Lipschultz Precision Immunology Institute, ISMMS, NY, NY, USA
12 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Fig. 8 from VSIG4 Restricts Hepatocellular Carcinoma Control by Suppressing Tumor-Specific CD8+ T-cell Immunity in the Tumor Microenvironment
Supplementary Fig. 8. Characteristics of WT littermate control and Vsig4-/- Kupffer cells in culture, Raji-VSIG4 cells, and human CD8+ T cell suppression by VSIG4-Ig
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig. 8 from VSIG4 Restricts Hepatocellular Carcinoma Control by Suppressing Tumor-Specific CD8+ T-cell Immunity in the Tumor Microenvironment
Supplementary Fig. 8. Characteristics of WT littermate control and Vsig4-/- Kupffer cells in culture, Raji-VSIG4 cells, and human CD8+ T cell suppression by VSIG4-Ig
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Fig. 4 from VSIG4 Restricts Hepatocellular Carcinoma Control by Suppressing Tumor-Specific CD8+ T-cell Immunity in the Tumor Microenvironment
Supplementary Fig. 4. Immune cells in the livers of Vsig4-/- and WT littermate control mice harboring 4-week MYC/NRASV12/SB11 HCC
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig. 4 from VSIG4 Restricts Hepatocellular Carcinoma Control by Suppressing Tumor-Specific CD8+ T-cell Immunity in the Tumor Microenvironment
Supplementary Fig. 4. Immune cells in the livers of Vsig4-/- and WT littermate control mice harboring 4-week MYC/NRASV12/SB11 HCC
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from NOTCH1 Drives Sexually Dimorphic Immune Responses in Hepatocellular Carcinoma
Sex-dependent immune responses in NOTCH1-driven liver tumors
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from NOTCH1 Drives Sexually Dimorphic Immune Responses in Hepatocellular Carcinoma
Sex-dependent immune responses in NOTCH1-driven liver tumors
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from NOTCH1 Drives Sexually Dimorphic Immune Responses in Hepatocellular Carcinoma
NOTCH1-driven tumors in females lead to impaired CD8+ T cell priming and activation
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from NOTCH1 Drives Sexually Dimorphic Immune Responses in Hepatocellular Carcinoma
NOTCH1-driven tumors in females lead to impaired CD8+ T cell priming and activation
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Fig. 5 from VSIG4 Restricts Hepatocellular Carcinoma Control by Suppressing Tumor-Specific CD8+ T-cell Immunity in the Tumor Microenvironment
Supplementary Fig. 5. CD4+ T cell intratumoral infiltration and IFNγ production in Vsig4-/- vs WT littermates 4 weeks after MYC/NRASV12/SB11 HCC induction
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig. 5 from VSIG4 Restricts Hepatocellular Carcinoma Control by Suppressing Tumor-Specific CD8+ T-cell Immunity in the Tumor Microenvironment
Supplementary Fig. 5. CD4+ T cell intratumoral infiltration and IFNγ production in Vsig4-/- vs WT littermates 4 weeks after MYC/NRASV12/SB11 HCC induction
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Fig. 7 from VSIG4 Restricts Hepatocellular Carcinoma Control by Suppressing Tumor-Specific CD8+ T-cell Immunity in the Tumor Microenvironment
Supplementary Fig. 7. Vsig4-/- mice show improved priming of antigen-specific CD8+ T cells in the antigen-expressing liver
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig. 7 from VSIG4 Restricts Hepatocellular Carcinoma Control by Suppressing Tumor-Specific CD8+ T-cell Immunity in the Tumor Microenvironment
Supplementary Fig. 7. Vsig4-/- mice show improved priming of antigen-specific CD8+ T cells in the antigen-expressing liver
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Fig. 1 from VSIG4 Restricts Hepatocellular Carcinoma Control by Suppressing Tumor-Specific CD8+ T-cell Immunity in the Tumor Microenvironment
Supplementary Fig. 1. VSIG4 is expressed in hepatic macrophages in both mouse and human healthy livers and HCC
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig. 1 from VSIG4 Restricts Hepatocellular Carcinoma Control by Suppressing Tumor-Specific CD8+ T-cell Immunity in the Tumor Microenvironment
Supplementary Fig. 1. VSIG4 is expressed in hepatic macrophages in both mouse and human healthy livers and HCC
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Fig.9 from VSIG4 Restricts Hepatocellular Carcinoma Control by Suppressing Tumor-Specific CD8+ T-cell Immunity in the Tumor Microenvironment
Supplementary Fig.9. Significant reduction of HCC burden in Vsig4-/- mice treated with the combination of anti-PD-L1 and anti-VEGF antibodies.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig.9 from VSIG4 Restricts Hepatocellular Carcinoma Control by Suppressing Tumor-Specific CD8+ T-cell Immunity in the Tumor Microenvironment
Supplementary Fig.9. Significant reduction of HCC burden in Vsig4-/- mice treated with the combination of anti-PD-L1 and anti-VEGF antibodies.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Fig. 6 from VSIG4 Restricts Hepatocellular Carcinoma Control by Suppressing Tumor-Specific CD8+ T-cell Immunity in the Tumor Microenvironment
Supplementary Fig. 6. IHC staining for mouse livers with HCC 4 weeks after HTVi of MYC/NRASV12/SB11 plasmids
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig. 6 from VSIG4 Restricts Hepatocellular Carcinoma Control by Suppressing Tumor-Specific CD8+ T-cell Immunity in the Tumor Microenvironment
Supplementary Fig. 6. IHC staining for mouse livers with HCC 4 weeks after HTVi of MYC/NRASV12/SB11 plasmids
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from NOTCH1 Drives Sexually Dimorphic Immune Responses in Hepatocellular Carcinoma
Mechanism of immune surveillance in males with NOTCH1 liver tumors
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from NOTCH1 Drives Sexually Dimorphic Immune Responses in Hepatocellular Carcinoma
Mechanism of immune surveillance in males with NOTCH1 liver tumors